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Abstract
Background: Sarcomas are one of the most refractory diseases among malignant tumors. More
effective therapies based on an increased understanding of the molecular biology of sarcomas are
needed as current forms of therapy remain inadequate. Recently, it has been reported that Wnt-
1/β -catenin signaling inhibits apoptosis in several cancers. In this study, we investigated the efficacy
of a monoclonal anti-Wnt-1 antibody in sarcoma cells.
Methods: We treated cell lines A-204, SJSA-1, and fresh primary cultures of lung metastasis of
sarcoma with a monoclonal anti-Wnt-1 antibody. Wnt-1 siRNA treatment was carried out in A-
204. We assessed cell death using Crystal Violet staining. Apoptosis induction was estimated by
flow cytometry analysis (Annexin V and PI staining). Cell signaling changes were determined by
western blotting analysis.
Results: We detected Wnt-1 expression in all tissue samples and cell lines. Significant apoptosis
induction was found in monoclonal anti-Wnt-1 antibody treated cells compared to control
monoclonal antibody treated cells (p < 0.02). Similarly, we observed increased apoptosis in Wnt-1
siRNA treated cells. Blockade of Wnt-1 signaling in both experiments was confirmed by analyzing
intracellular levels of Dishevelled-3 and of cytosolic β -catenin. Furthermore, the monoclonal anti-
Wnt-1 antibody also induced cell death in fresh primary cultures of metastatic sarcoma in which
Wnt-1 signaling was active.
Conclusion: Our results indicate that Wnt-1 blockade by either monoclonal antibody or siRNA
induces cell death in sarcoma cells. These data suggest that Wnt-1 may be a novel therapeutic
target for the treatment of a subset of sarcoma cells in which Wnt-1/β -catenin signaling is active.
Background
Sarcomas are highly malignant neoplasms that arise from
mesenchymal tissues and the mechanism by which mes-
enchymal tissues undergo neoplastic transformation is
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largely unknown. Despite progress in the multidiscipli-
nary treatment (surgery, chemotherapy, and radiation) of
sarcomas, the results of these treatments in advanced dis-
ease remain unsatisfactory and the majority of these
patients die from disseminated metastatic disease.
Approximately 11,000 cases are diagnosed in the United
States annually and 45 % of these patients will go on to
die of their disease [1]. New therapies based on an
improved molecular understanding of sarcomas are
needed.
Recently, it has been reported that the Wnt pathway may
be activated in several sarcomas [2-5]. Wnt signaling is
essential for development and organogenesis [6,7]. It has
been shown that the Wnt pathway is associated with
tumor development and/or progression. We previously
identified the overexpression of Dishevelled-3 (Dvl-3), a
critical mediator of Wnt signaling, in non-small cell lung
cancer and malignant pleural mesothelioma [8,9]. Wnt
proteins, including Wnt-1, have been shown to be
expressed in several cancers. We have developed a mono-
clonal anti-Wnt-1 antibody. In previous studies, we have
demonstrated its efficacy in induction of apoptosis in
human cancer cell lines and shown that the antibody lacks
general toxicity in cells lacking the Wnt-1 protein [10-12].
This report suggests that the monoclonal anti-Wnt-1 anti-
body may also be efficacious in refractory sarcomas if
Wnt-1/β -catenin signaling exists in these sarcomas. In the
present study, we address this hypothesis and demon-
strate a possible therapeutic role of this monoclonal anti-
Wnt-1 antibody in the treatment of sarcoma cells.
Methods
Cell lines and tissue samples
Human sarcoma cell lines, A-204 (origin: muscle) and
SJSA-1 (origin: bone) were obtained from the American
Type Culture Collection (ATCC, Manassas, VA). A-204
and SJSA-1 were cultured in McCoy's 5a medium and
RPMI 1640 respectively, with 10% fetal bovine serum,
penicillin (100 IU/ml), and streptomycin (100 µg/ml).
Both cells were cultured at 37°C in a humid incubator
with 5% CO2. Fresh tissue samples of lung metastasis of
sarcoma were obtained with consent from patients under-
going resection. They were cut into small pieces (1–2 mm
in diameter), and digested with Collagenase A (Roche
Applied Science, Indianapolis, Indiana) at room tempera-
ture for 2 hours according to manufacture's protocol. Sin-
gle cells from the digestion were spun down and the cell
pellets were washed twice using RPMI 1640 supple-
mented with 10% fetal bovine serum, penicillin (100 IU/
ml) and streptomycin (100 µg/ml). Then, the cells were
resuspended in the same medium and cultured in 6-well
plates at 37°C in a humid incubator with 5% CO2 until
they were ready for treatments. Other fresh tissue samples
of lung metastasis of sarcoma were immediately snap-fro-
zen in liquid nitrogen. They were kept at -170°C in a liq-
uid nitrogen freezer before use.
Western blotting
Whole cell lysates in tissue samples were obtained with T-
Per Mammalian Protein Extraction Reagent (Pierce, Rock-
ford, IL). Whole cell lysates in A-204 and SJSA-1 cell lines
were obtained with M-Per Mammalian Protein Extraction
Reagent (Pierce, Rockford, IL). Cytosolic proteins were
prepared according to a previously described protocol [9].
The aliquots were separated on 4–15% gradient SDS-poly-
acrylamide gels and transferred to Immobilion-P (Milli-
pore, Bedford, MA) membranes. Antigen-antibody
complexes were detected by ECL blotting analysis system
(Amersham Pharmacia Biotech, Piscataway, NJ). The fol-
lowing primary antibodies were used: Wnt-1 (custom-
made, Rockland Inc., Gilbertsville, PA); Dvl-1, Dvl-2, Dvl-
3, Survivin (Santa Cruz Biotechnology, Santa Cruz, CA);
β -catenin (Transduction Laboratories, Lexington, KY);
and β -Actin (Sigma Chemical Co., St Louis, MO).
Antibody incubation with cells
The anti-Wnt-1 mouse monoclonal antibody (IgG1) was
custom-made at Rockland Inc. (Gilbertsville, PA). The
control monoclonal antibody (Sigma-Aldrich Co., St
Louis, MO) used was the same subtype as the anti-Wnt-1
monoclonal antibody (IgG1). Cells were plated into six-
well plates one day before experiments. Then normal
medium was replaced by media containing antibodies at
10 µg/ml concentration and the cells were incubated at
37°C in a humid incubator with 5% CO2. Each experi-
ment was performed at least 3 times.
Apoptosis analysis
Cells were harvested by trypsinization and stained using
an Annexin V-FITC Apoptosis kit (BioSource, Camarillo,
CA), according to the manufacturer's protocol. Stained
cells were immediately analyzed by flow cytometry (FAC-
Scan; Becton Dickinson, Franklin Lake, NJ). Early apop-
totic cells with exposed phosphatidylserine but intact cell
membranes bound to Annexin V-FITC but excluded pro-
pidium iodide (PI). Cells in necrotic or late apoptotic
stages were labeled with both Annexin V-FITV and PI.
Experiments were performed in triplicate and a total of
20000 cells were analyzed in each individual experiment.
RNA interference
Cells were plated into a six-well plate with fresh media
without antibiotics 24 hours before testing. The ion
exchange high-performance liquid chromatography-puri-
fied siRNAs (Wnt-1 siRNA and nonsilencing siRNA con-
trol, >97% pure) were purchased from Qiagen-Xeragon
(Germantown, MD). The siRNA-targeted human Wnt-1 is
derived from a mRNA sequence (GGTTCCATCGAATCCT-
GCA) of human Wnt-1. The control (nonsilencing) siRNABMC Cancer 2005, 5:53 http://www.biomedcentral.com/1471-2407/5/53
Page 3 of 7
(page number not for citation purposes)
does not target any known mammalian gene (the targeted
sequence is AATTCTCCGAACGTGTCACGT). The lyophi-
lized siRNA were dissolved in annealing buffer and
reheated to 95°C for 1 minute followed by 1 hour at 37°C
incubation. We followed the protocol described by Elba-
shir et al with some modifications [13]. After siRNA trans-
fection, we incubated plates at 37°C before further
analysis.
Statistical analysis
Data shown represent mean values (± S.D.). Student's t-
test was used for comparing different treatments and cell
line.
Results
Detection of Wnt-1/ β -catenin signaling in tissue samples 
of metastatic sarcoma and sarcoma cell lines
The expression of Wnt-1, Dvl-1, 2, 3 and cytosolic β -cat-
enin was analyzed in 6 tissue samples of metastatic sar-
coma, A-204 and SJSA-1 cell lines. The expression of Wnt-
1, Dvl-3 and cytosolic β -catenin was found in all tissue
samples and both cell lines (Figure 1). Dvl-1 and Dvl-2
were minimally expressed or not expressed in all tissue
samples (data not shown). These results indicate that
Wnt-1/β -catenin signaling may be activated in sarcoma
cells.
The monoclonal anti-Wnt-1 antibody induces apoptosis in 
A-204 cell line
Next, the monoclonal anti-Wnt-1 antibody [10,11] was
utilized for treating the sarcoma cell lines A-204 and SJSA-
1. Cell death was found after 7 days of treatment with the
monoclonal anti-Wnt-1 antibody (Figure 2A). By flow
cytometry analysis, we found significant apoptosis induc-
tion in A-204 cell line (Figure 2B)(p < 0.02). In contrast,
no noticeable effect was found after control monoclonal
antibody treatment.
Tissue samples of metastatic sarcoma and sarcoma cell lines express Wnt-1 signaling mediators Figure 1
Tissue samples of metastatic sarcoma and sarcoma cell lines express Wnt-1 signaling mediators. Cases 1–6: tissue samples (1,3 
and 6;osteosarcoma, 2;synovical sarcoma, 4;liposarcoma, 5;leiomyosarcoma).
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(A) 0.5% Crystal Violet staining of A-204 and SJSA-1 cell lines after the monoclonal anti-Wnt-1 antibody treatment (7 days  after treatment) Figure 2
(A) 0.5% Crystal Violet staining of A-204 and SJSA-1 cell lines after the monoclonal anti-Wnt-1 antibody treatment (7 days 
after treatment). The concentration of both control and monoclonal anti-Wnt-1 antibodies used was 10 µg/ml. The mono-
clonal anti-Wnt-1 antibody induced cell death. (B) Apoptosis analysis using flow cytometry after the monoclonal anti-Wnt-1 
antibody treatment (10 µg/ml for 6 days) in A-204 cell line. The results (percentage of apoptotic cells) are the mean ± SD 
(error bars). Significant apoptosis induction was observed in the monoclonal anti-Wnt-1 antibody treatment compared to the 
control monoclonal antibody treatment (p < 0.02). (C) Western analysis after the monoclonal anti-Wnt-1 antibody treatment 
(10 µg/ml for 6 days) in A-204 and SJSA-1 cell lines. β -Actin served as a loading control. Decreased levels of Dvl-3 and of 
cytosolic β -catenin confirmed the blockade of Wnt-1 signaling.
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(A) Apoptosis and (B) expression of Wnt-1 signaling mediators analysis after Wnt-1 siRNA treatment (200 nM for 4 days) in A- 204 cell line Figure 3
(A) Apoptosis and (B) expression of Wnt-1 signaling mediators analysis after Wnt-1 siRNA treatment (200 nM for 4 days) in A-
204 cell line. The results were similar to that of the monoclonal anti-Wnt-1 antibody treatment.
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The monoclonal anti-Wnt-1 antibody inhibits Wnt-1/β -
catenin signaling
The blockade of Wnt-1 signaling in A-204 and SJSA-1 cell
lines was confirmed by analyzing the levels of Wnt-1
downstream mediators (Figure 2C). Dvl-3 and β -catenin
protein levels decreased after the monoclonal anti Wnt-1
antibody treatment. Survivin, an inhibitor of apoptosis,
was also downregulated.
RNA interference
Next, we investigated the effects of silencing Wnt-1 expres-
sion through RNA interference. Apoptosis induction by
Wnt-1 siRNA was similar to that by anti-Wnt-1 mono-
clonal antibody (Figure 3A). Moreover, we confirmed the
blockade of Wnt-1 signaling in A-204 cells after Wnt-1
siRNA treatment (nonsilencing siRNA as control) by west-
ern blot analysis (Figure 3B).
The monoclonal anti-Wnt-1 antibody induces cell death in 
fresh primary cultures of metastatic sarcoma
After confirmation of the efficacy of monoclonal anti-
Wnt-1 antibody treatment in A-204 and SJSA-1 cells, we
tested its ability to induce cell death in fresh primary cul-
tures of metastatic osteosarcoma that has activated Wnt-1/
β -catenin signaling (Cases 3 and 6). The cell death was
found after 5 to 7 days of the antibody treatment, whereas
no noticeable effect was found in these fresh samples after
control monoclonal antibody treatment (Figure 4).
Discussion
Wnt signaling consists of an intracellular cascade that
involves Frizzled, Dvl, glycogen synthase kinase-3β , β -cat-
enin and T Cell Factor (TCF)/Lymphocyte Enhancer Bind-
ing Factor (LEF) [14,15]. It is thought that a component of
cancer induction and progression results from elevated
intracellular β -catenin levels [16]. It has been reported
that Wnt signaling is associated with the progression of
osteosarcoma [17]. Translocation of β -catenin to the cyto-
plasm and/or nucleus of osteosarcoma cells was detected
in five resected cases of pulmonary metastasis, although
seven primary osteosarcoma cells that did not metastasize
for more than five years did not show β -catenin expres-
sion [18].
Wnt-1 was originally described as a proto-oncogene in
mouse mammary tumor induced by mouse mammary
tumor virus [19]. Chen et al. reported that Wnt-1 signaling
inhibited apoptosis through β -catenin and that cells
expressing Wnt-1 resisted apoptosis induction by chemo-
therapy [20]. Recently, it has been reported that a polyclo-
nal anti-Wnt-1 antibody can downregulate β -catenin/TCF
activity and induce apoptosis in head and neck squamous
cell carcinoma [21]. In addition, we demonstrated that
both a monoclonal anti-Wnt-1 antibody and Wnt-1
siRNA induced apoptosis in human cancer cells [10-12].
These reports strongly suggest that Wnt-1 signaling plays
a critical role in the survival of malignant cells. We treated
A-204, SJSA-1 cells and fresh primary cultures with the
monoclonal anti-Wnt-1 antibody after confirmation of
Wnt-1/β -catenin signaling in sarcoma cells. The antibody
induced cell death in these sarcomas and decreased levels
of Dvl-3 and β -catenin in A-204 and SJSA-1 cell lines. Fur-
thermore, Wnt-1 siRNA induced similar effects. These
results indicate that Wnt-1 signaling may play a critical
role in the survival of a subset of sarcoma cells. However,
much work remains in order to gain a clear understanding
of the pathway.
Conclusion
Our results indicate that the monoclonal anti-Wnt-1 anti-
body induces cell death in sarcoma cells. These findings
suggest that Wnt-1 inhibition may be of therapeutic inter-
est in a subset of sarcomas in which Wnt-1/β -catenin sig-
naling is active.
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